Skip to main content
Caplight Logo









BioEclipse Therapeutics

BioEclipse Therapeutics

Private
Mountain View, CaliforniaHealthcare & Life Scienceshttps://www.bioeclipse.com/

Last Round

Grant

Apr 26, 2022

Total Funding Raised

$17.3M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BioEclipse Therapeutics is a biotechnology company that develops immuno-oncology therapeutics designed to kill tumor cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologycell therapyoncolytic virussolid tumor treatmentcancer immunotherapyautologous cell therapyallogeneic cell therapyoff-the-shelf therapycytokine-induced killer cellsCIK cellsbiotech startupclinical-stage biotechdrug developmentprecision medicinecancer research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioEclipse Therapeutics Comparables

Compare BioEclipse Therapeutics with similar companies based on industry and business-model similarity.

BioEclipse Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Calidi Biotherapeutics
78%
Genelux Corporation
77%
EpicentRx
76%

BioEclipse Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 26, 2022
CrowdfundingJan 19, 2022
Series AJun 24, 2019
SeedJul 21, 2016

Key People

Founding team and executive leadership

Pamela Contag

CEO And President

Executive Team

Mahmoud Mahmoudian

Board Of Directors, Chief Business Officer

Executive Team

BioEclipse Therapeutics Investors

Notable investors and investment history

BioEclipse Therapeutics investors
InvestorRounds
Revelis Capital GroupSeries A
Plum Alley InvestmentsSeries A
Foothill VenturesSeries A
California Institute for Regenerative MedicineGrant
TSV CapitalSeries A
DEFTA PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 152% MoM.

  • Apr 16, 2026

    Monthly visitors increased 61% MoM.

BioEclipse Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BioEclipse Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BioEclipse Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMountain View, California
Employee Range7
Year Founded2006
Last FundingApr 26, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?